The Global Health Body Issues Alert Over Acute Lack of Obesity Injections

Fewer than 10% of people who could benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it releases its initial guidance on the medications.

With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments.

According to estimates, more than two billion will be obese by 2030 without intervention.

"Our new guidance affirms that obesity is a lifelong illness that can be managed with thorough and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are major obstacles to universal access to the injections that can aid individuals in losing substantial body mass, explains the body.

Skinny Jab Supply Crisis

Even under the present most optimistic case, the manufacturing of these medications would only suffice for about 100 million people – fewer than 10% of eligible patients, according to the WHO.

The advice calls on governments and firms to increase availability, via strategies including patent sharing.

Exclusive production rights on semaglutide – the primary component of a leading brand – is due to expire in a number of nations in 2026.

How Obesity Jabs Operate

These medications replicate a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so users reduce food intake.

Patients typically begin shedding pounds after several weeks of starting on the regular doses.

Evidence points to people may see weight return within a year of halting the drug, as their typical hunger resume.

To be overweight or obese raises your risk for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity impacts people in every country and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.